Publication | Closed Access

SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis

Hepatic Stellate CellsImmunologyPathologyFatty Liver DiseaseInflammationMetabolic SyndromeNonalcoholic Fatty Liver DiseaseHepatology FibrosisCell SignalingHealth SciencesMetabolic Associated SteatohepatitisFibrosisSglt2 Inhibitor EmpagliflozinLiver PhysiologyTargets Grem2Hepatology InflammationMicrorna DetectionCell BiologyHepatologyLiver DiseaseMedicine